A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...

Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...

Reoperation in recurrent glioblastoma patients may improve progression-free and overall survival, especially when tumors are in non-eloquent, accessible brain regions. Factors like age, gender, tumor ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company” or "Plus Therapeutics”), a clinical-stage pharmaceutical company ...

Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma ...